NEA has led a series B round for cancer treatment developer Pionyr Immunotherapeutics, co-founded by researchers from UC San Francisco and University of Toronto.
US-based immuno-oncology developer Pionyr Immunotherapeutics raised $62m in series B funding yesterday from a consortium that featured spinout-focused investment firm Osage University Partners (OUP).
New Enterprise Associates (NEA) led the round, which also included Sofinnova Ventures, Vida Ventures, Orbimed, SV Health Investors and Mission Bay Ventures.
Founded in 2015 as Precision Immune, Pionyr is creating antibody therapeutics to boost the body’s antitumour immunity. Its approach balances the tumour microenvironment to favour immune-activating myeloid cells over immune-suppressing ones.
The company has…